The morphological detection of early neoplastic transformation leading to cervical cancer remains problematic. In this work, we have identified deleted in split hand/split foot 1 protein (DSS1) as an early biomarker that is specifically upregulated in premalignant and malignant cervical epithelial cells, but is low or undetectable in non-malignant cells. DSS1 mRNA and protein levels are significantly increased in cultured human cervical carcinoma cell lines originating from primary and metastatic tumors. In fact, > 96% of patient tumor tissues were found to have cells with elevated DSS1 when compared with tumor-adjacent normal cells. In histological sections of cervical tissue containing either invasive cervical carcinoma or its precursor lesions, DSS1 was readily detected in the tumor cells. Steady-state DSS1 expression by immortalized cervical cancer cell lines was found to be necessary for maintenance of their transformed phenotype, since stable shRNA-mediated depletion of DSS1 in HeLa cells inhibited their proliferation and colony-forming activity in monolayer cultures and prevented division of these cells in soft agar. When DSS1 levels are reduced using shRNA, the cells ultimately undergo apoptosis via activation of p53 and the p53 downstream targets, and cleavage of apoptosis-associated proteins including CPP32/caspase-3, poly(ADP-ribose)polymerase and DNA-PKcs. In addition, silencing of DSS1 makes cervical cancer cells sensitive to cell death after treatment with cisplatin. We conclude that the DSS1 protein is critically involved in the maintenance of the transformed phenotype in cervical cancer cells, and that it might be a specific, robust and reliable marker for early detection, diagnosis and treatment.
Introduction
Cervical cancer is a major cause of cancer-related death in women worldwide, in spite of extensive efforts to encourage regular Pap tests, therapeutic and surgical interventions, and recent advances in vaccination against human papillomaviruses (HPVs) (1, 2) . The development of cervical cancer is a multistep process consisting of initiation, promotion and progression; however, the molecular mechanisms that accompany progression from low-grade squamous intraepithelial lesions (LSIL) to fully developed malignant tumors are still poorly understood. HPV infection is considered to be the most significant predisposing factor for development of human cervical carcinogenesis (3) . Although cervical infection with high-risk types of HPV (i.e. HPV16, 18, 31, 33 and 45) is common, only small numbers of HPV-infected patients will develop precancerous lesions such as cervical intraepithelial neoplasia (CIN), and even fewer progress into more advanced cervical cancers [e.g. squamous cell carcinomas (SCCs), adenocarcinomas (AdCs) and adenosquamous cell carcinomas (AdSCCs] (1). Thus, HPV infection by itself is not sufficient to cause cervical cancer, and other unknown cofactors must come into play before tumors can develop (4) .
At the molecular level, HPV infection is associated with or drives genetic and epigenetic dysregulation of the infected cell's growthcontrolling genes (4, 5) . For example, HPV integration into the host cell genome is accompanied by loss of E2, resulting in uncontrolled expression of the HPV oncoproteins, E6 and E7 (6) . Overexpressed E6 protein then binds to p53 and targets it for degradation through ubiquitin-proteasome system, eventually leading to an inhibition of p53's growth regulatory functions (7) , and overexpressed E7 functionally inactivates the retinoblastoma and related pocket proteins, resulting in a release of free E2F and transcription of genes that promote cellular proliferation (8) . We have previously reported that the catalytic alpha polypeptide of phosphoinositide-3-kinase (PIK3CA) is involved in the development of cervical cancer (9) , by way of the PI3K/AKT signaling pathway, which regulates cellular proliferation and apoptosis (10, 11) . In cervical cancer cell lines harboring amplified PIK3CA, expression of the p110α component of PIK3CA is increased and gives elevated kinase activity to whole enzyme (9) . In addition, the transformed phenotype of these cells is significantly reduced by treatment with LY-294002, a potent and specific PI3K inhibitor. This suggests that increased PIK3CA expression and activity may promote proliferation and reduce apoptosis during cervical cancer development (9) .
A highly conserved small acidic protein, called Deleted in Split hand/Split foot 1 (DSS1), is now known to be involved in many biological and cellular processes, including development (12) , differentiation (13) , genome stability (14) (15) (16) , homologous recombination (17) (18) (19) , DNA repair (20, 21) , cellular proliferation and neoplastic transformation (22) , protein degradation (23) (24) (25) and mRNA export (26) . Its encoding gene DSS1, which is located on human chromosome 7q21.3-q22.1, was originally identified as being deleted in patients with a dominant inherited heterogeneous limb developmental disorder called ectrodactyly or split hand/split foot malformation type 1 (12) . We have shown previously that DSS1 elevation occurs in skin cells of v-Ha-ras-initiated Tg.AC transgenic mice treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) tumor promoter to cause tumors (22) . More recently, we have also shown that DSS1 participates in ubiquitination of p53 by protein-protein interactions involving the RPN3/S3-interacting motif (R3IM), which is located in the N-terminus of DSS1 (25) .
We report here, for the first time, that DSS1 is critical for proliferation and transformation of cervical epithelial cells, and that it might be a reliable biomarker for early detection, diagnosis and treatment of human cervical cancer. DSS1 expression was found to be elevated in the proliferative squamous or glandular regions of the human cervical carcinoma tissue, even in premalignant lesions of the uterine cervix. Furthermore, patients with different tumor grades and/or clinical stages of cervical cancer exhibited significantly higher expression levels of DSS1 in tumor tissue when compared with tumor-adjacent normal cervical tissue. Finally, we report that enforced lowering of DSS1 protein levels in cervical carcinoma cell lines inhibits cell proliferation and neoplastic transformation and causes apoptosis through a p53-dependent CPP32/caspase-3-mediated apoptotic pathway. Taken together, these results suggest that DSS1 may supply the second oncogenic change, following HPV infection, leading to cervical carcinoma development from HPV-infected cervical epithelial cells.
Materials and methods

Collections of human cervical samples and cell lines
One set of clinical cervical specimens was collected from September 2005 through August 2008 at Chang Gung Memorial Hospital in Taiwan (27) . The specimen donors were from patients with high-grade squamous intraepithelial lesions (CIN2 and CIN3), and from patients with early FIGO (The International Federation of Gynecology and Obstetrics) stages of cervical carcinomas receiving radical surgery. Enrollment of specimen donors was performed by a procedure that has been reviewed and approved by the Institutional Review Board (IRB) in Taiwan for the proposed activities. A second set of human specimen donors provided 26 individually matched normal/tumor tissue pairs, obtained from Protein Biotechnologies (San Diego, CA). Recruitment of these cervical tumor tissue donors was under strict IRB-approved protocols, with informed consent and the utmost attention to issues of patient safety, anonymity and confidentiality. Finally, normal and malignant human cervical cell lines were obtained from the American Type Culture Collection (ATCC). These cells were cultured in complete medium, as indicated by ATCC, at 37°C in a humidified 95% air/5% CO 2 incubator. The complete medium was supplemented with 10% fetal bovine serum (FBS), penicillin (100 IU/ml), streptomycin sulfate (100 µg/ml), l-glutamine (2 mM) and sodium pyruvate (1 mM). HeLa, C-33A and MS751 were grown in modified Eagle's medium (MEM); HeLa S3, HS68 and HNF in Dulbecco's MEM; ME-180 and SiHa in McCoy's 5A; HT-3 and CaSki in RPMI-1640; C-4I and C-4II in Waymouth's MB752/1. Human normal primary epidermal keratinocytes (ATCC) isolated from neonatal foreskin were grown in serum-free Dermal Cell Basal Media (ATCC) supplemented with Keratinocyte Growth Kit (ATCC) components. All cell lines were routinely checked for mycoplasma contamination.
Preparation of total RNAs, cDNA synthesis and RT-PCR
Total RNAs were isolated using the TRIZOL reagent according to the manufacturer's manual (Invitrogen, Carlsbad, CA). The single-stranded cDNAs prepared from total RNAs using MMLV SuperScript II reverse transcriptase and oligo-dT primer were employed as a template for PCR. The primers used for PCR were as follows: DSS1 sense, 5′-CACCATGTCAGAGAAAAAGCA GCCGGTA-3′; DSS1 antisense, 5′-CCGGGCTGAAGTCTCCATCTTAAACCATG-3′; β-actin sense, 5′-CACCATCATGAAGTGTGACGTGGACATC-3′; β-actin antisense, 5′-CTAGAAGC ATTTGCGGTGGACGATG-3′. The primers were synthesized in the DNA Core Facility of the UT Health Science Center (San Antonio). PCR was performed in denaturation (94°C for 45 s), annealing (58°C for 45 s) and extension (72°C for 2 min) cycles, for 30 repetitions, in a Perkin-Elmer 9600 thermal cycler (Applied Biosystems, Carlsbad, CA). The PCR product was analyzed on 2% agarose gels and visualized under ChemiDoc/XRS systems (Bio-Rad, Hercules, CA).
Protein extraction and immunoblotting
All patients received the defined surgical treatment for given diagnoses: cone biopsy for CIN 2/3 and radical hysterectomy for early invasive carcinoma. Twenty-six individually matched normal/tumor tissue pairs from patients with various grades and/or stages of cervical cancer were prepared by a pathologist from surgically removed materials. Tumor-adjacent normal tissues were carefully dissected to avoid contamination by tumor cells, while leaving the tumor samples free from normal tissues. Each histological diagnosis was confirmed by a second pathologist. The matched normal/tumor tissues were then prepared for immunoblotting (IB) as indicated in the data sheet of Protein Biotechnologies. On the other hand, the cells were first dissociated by trypsinization and washed once with 1× ice cold phosphate-buffered saline, and then they were lysed at 4°C in modified RIPA buffer. After 10 min, the lysates were centrifuged at 14 000g (Eppendorf, Hauppauge, NY) for 15 min at 4°C. The protein concentrations in the lysates were determined by bicinchoninic acid assay assay (Pierce, Rockford, IL). Equal amounts of proteins from different samples were separated electrophoretically on 4-12% Bis-Tris/sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and then transferred to Hybond membrane (GE Healthcare, Piscataway, NJ). The membrane was incubated with primary antibodies, including anti-DSS1 (BioSource, Carlsbad, CA), anti-p53 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-p21 WAF1/CIP1 (Pharmingen, San Jose, CA), anti-CPP32/caspase-3 (Cell Signaling Technology, Danvers, MA), anti-poly(ADP-ribose)polymerase (PARP) (Cell Signaling), anti-DNAPKcs (MBL, Woburn, MA) and anti-actin (Sigma-Aldrich, St Louis, MO).
Immunoreactive protein bands were visualized using horseradish peroxidase (HRP)-conjugated mouse or rabbit IgG at 1:3000, and detected by enhanced chemiluminescence (GE Healthcare).
Immunohistochemistry
Archived tissue blocks of formalin-fixed, paraffin-embedded cervical tissues were obtained from diagnostic pathology laboratories. All of the sections had been evaluated by a clinical pathologist after hematoxylin and eosin staining (27) . The paraffin sections were processed for blotting onto tissue array slides as described previously (31) . The array slides contained spot tissues from tumors at distinct progressive cervical carcinoma stages, ranging from individual adjacent normal cervix, CIN2 (moderate dysplasia), CIN3/CIS (severe dysplasia/carcinoma in situ) and invasive carcinomas, including SCCs and nonSCCs (AdCs and AdSCCs). The array slides and full paraffin sections were incubated at 50-60°C for 10 min, and then de-paraffinized and re-hydrated by three successive washes in xylene and graded alcohols (100% → 95% → 70%). Heat-induced antigen retrieval was performed by incubation of the slides 70-75°C for 10 min in 10 mM sodium citrate. The arrays and sections were blocked with a proteinaceous blocking solution and then incubated at 4°C overnight with anti-DSS1 rabbit polyclonal antibody (Abnova, Taipei City, Taiwan) (1:100), followed by the addition of anti-rabbit secondary antibody conjugated with HRP polymer and diaminobenzidene substrate (Super Sensitive TM Polymer-HRP IHC Detection System plus DAB) (BioGenex, Fremont, CA). When adequate color development was seen, the slides were washed in water to stop the reaction, counterstained and covered with a mounting medium. The specificity of antibody binding was validated by addition of DSS1 fusion protein to the antibody, followed by precipitation of antigen-antibody depletion of the immunogenic epitopes pairs and subsequent testing of the antibody for loss of its ability to bind to DSS1 on sections. The micrographs were taken under the light microscope (Leica, Allendale, NJ). The grades of DSS1 staining were evaluated by pathologists using the following categories (1): Score 0 was defined as no staining or dark cytoplasmic/nuclear staining of widely scattered cells (2); Score 1+ was considered as focal moderate staining in <50% of cells or pale cytoplasmic/nuclear staining in any proportion of cells not easily seen under a low power field (3); Score 2+ was evaluated as focal darkly staining areas (<50% of cells) or moderate cytoplasmic/nuclear staining of >50% of cells (4); Score 3+ was graded as dark cytoplasmic/nuclear staining that was easily visible with a low power objective and involves >50% of cells.
Construction for DSS1 small hairpin RNA
Pre-designed silencer select negative controls, NC1 and NC2, and three specific siRNAs (Ambion, Carlsbad, CA), complementary to DSS1 RNA sequence, were validated by qPCR and IB, as described in our earlier studies (25) . Two hairpin oligonucleotides with negative control 1 (NC1) and DSS1-specific siRNA sequences (shDSS1) were synthesized from Sigma-Aldrich. NC1 sense: 5′-TCTCGTAACGACGCGACGACTAATTC TTCCTGTCAAATTACGTCGTCGC GTCGTTACCT-3′; NC1 antisense: 5′-CTGCAGGTAACGACGCGACGACGTAATTTGACAG GAAGAATTAC GTCGTCGCGTCGTTAC-3′; shDSS1 sense, 5′-TCTCGGATA ATTGGGA TGA TGACCTTCCTGTCAGTCATCATCCCAATTATCCCT-3′; shDSS1 antisense, 5′-CTGCAGGG ATAATTGGGATGATGACTGACAGGAAGGT CATCATCCCAATTATCC-3′. Two oligos were denatured and re-annealed to form a duplex DNA that contains the small hairpin siRNA target sequence. The insert was then ligated into pGeneClip TM vector (Promega, Madison, WI) with the antibiotic marker hygro for selection of stable clones in eukaryotic cells.
Selection of the stable shDSS1 clones by RNAi-mediated gene silencing
Transfection of mammalian cells was carried out as described in Amaxa's protocol (Lonza, Walkersville, MD). In brief, 2 × 10 6 cells were electroporated with 4 µg of pGeneClip/NC1 or pGeneClip/shDSS1 in 100 µl of solution R by using program I-013 of the Nucleofector Device of Amaxa (Lonza). Cells were grown in the presence of Hygromycin B (400 µg/ml) to maintain the selection for 2-3 weeks at 37°C in a humidified 95% air/5% CO 2 incubator. DSS1 protein levels in the stable clones knocked down by DSS1 shRNA were compared using IB with a specific DSS1 antibody.
Focus-forming activity assay
Cells were seeded at 2 × 10 3 or 5 × 10 2 in 10 cm culture plates. Following selection with Hygromycin B (400 µg/ml) for 2-3 weeks, foci were fixed with 4 ml of 10% formalin at room temperature. After 2 h fixation, foci were stained with 3 ml of 1% Rhodamine B for 1 h at room temperature. The plates were washed under gentle stream of deionized water and placed upside down on bench to dry. The numbers of foci were counted in triplicate as described previously (22, 28, 29) .
Anchorage independence assay
Colony formation in soft agar was performed as described previously (22, 28, 29) . In 60 mm culture dishes, cells were re-suspended at 1 × 10 4 in 0.33%
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Noble Agar (Difco, Franklin Lakes, NJ) in 10% FBS/MEM and layered over 5 ml of 0.5% agar in MEM with 10% FBS. Cells were grown in the presence of Hygromycin B (400 µg/ml) to maintain the selection at 37°C in a humidified 95% air/5% CO 2 incubator. Eighteen days after seeding, colonies with >8 cells were counted and photographed under light microscopy (DMI 6000B, Leica).
DNA ladder assay
Cellular DNA fragments were isolated as described previously (30) . Adherent and non-adherent cells were pooled and lysed with buffer consisting of 50 mM Tris-HCl (pH = 7.5), 20 mM ethylenediaminetetraacetic acid and 1% NP-40.
After centrifugation for 1 min at 800g (Eppendorf), the supernatant with DNA fragments was collected. The supernatant was brought to 1% sodium dodecyl sulfate, digested with DNase-free RNase A (0.2 µg/µl) at 50°C for 1 h, and then reacted with proteinase K (2.5 µg/µl) at 37°C overnight. DNA was extracted using phenol/chloroform, precipitated with 1/10 vol of 3M sodium acetate and 2.5 vol of 100% ethanol and then dissolved in 10 mM Tris-HCl/1 mM ethylenediaminetetraacetic acid (pH = 7.6). The DNA fragments were separated by electrophoresis on 1.2% agarose gels and visualized by ChemiDoc/XRS systems (Bio-Rad).
Expression vector construction
Full-length human DSS1 cDNA fragment was generated by RT-PCR from HeLa total RNA using forward (5′-CACCGCGATCGCCATGTCTGAA AAGAAGCAGCC-3′) and reverse primers (5′-CTCGAGACGCGTTGATG TCTCCATCTTGTAGCCGTGCTT-3′), and the amplified blunt-end cDNA was directly cloned into the pcDNA3.1D/V5-His-TOPO C expression vector (Invitrogen). The pcDNA3.1D/DSS1-V5-His plasmid was digested sequentially with Mlu I and Sgf I enzymes and the DSS1 insert was ligated into a retroviral vector pQCXIP, harboring a DNA sequence encoding a HTBH tag at its C-terminus (His6-TEV-Biotinylated region-His6) (kindly provided by Dr Lan Huang, Physiology and Biophysics, University of California, Irvine), using a LigaFast TM Rapid DNA Ligation System (Promega). All the construct sequences were verified using an automated Applied Biosystems sequencer and the ABI PRISM TM BigDye TM Terminator Cycle Sequencing Ready
Reaction Kit (Applied Biosystems). Plasmid DNAs were prepared using purification kits from Qiagen (Valencia, CA) and were endotoxin-free when used for transfection into mammalian cells.
Cell transduction
The packaging cells RetroPack TM PT-67 (Clontech, Mountain View, CA) were transfected with pQCXIP-HTBH or pQCXIP-DSS1-HTBH retroviral DNA using Lipofectamine/PLUS TM reagents (Invitrogen). After 48 h of transfection, the viruscontaining medium was collected, filtered and used for targeting into HeLa cells by infection. The recombinant pQCXIP retroviral vector carries HTBH tag or human DSS1-HTBH gene driven by the cytomegalovirus promoter and puro R gene driven by the long terminal repeat promoter. The virus-infected HeLa stable clones were obtained after at least 2-3 weeks of selection in 10% FBS/MEM medium with 1 µg/ml puromycin (Sigma-Aldrich). Stable clones were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis/IB using Streptavidin-HRP at 1:3000 to confirm the protein expression of HTBH or DSS1-HTBH.
Statistical analysis
A logistic regression model was employed to examine the effects of strong DSS1 immunohistochemistry (IHC) expression with score of 3+ on each of the pathological risk factors, and the univariate (unadjusted) and multivariate (adjusted) odds ratios in logistic regression were calculated. All statistical analyses were performed by using SPSS 17.0. P < 0.05 was considered statistically significant. Data were also subjected to statistical analysis by one-way analysis of variance (PRISM software version 4.0; GraphPad, San Diego, CA) or Student's t-test.
Results
Overexpression of DSS1 in human cervical cancer cell lines and in clinical specimens
Our previous studies have demonstrated that the DSS1 plays a critical role in early skin carcinogenesis (22) . Therefore, we hypothesized that 
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DSS1 may act as a cofactor to promote proliferation and malignant transformation of the cervical epithelium as well, toward the development of cervical cancer. To test this hypothesis, we first compared DSS1 mRNA and protein expression levels by RT-PCR and IB, respectively, in two kinds of immortalized human cervical carcinoma cell lines: one set derived from primary tumors (HeLa, HeLa S3, C-4 I, C-4 II, C-33A and SiHa), and the second set derived from distant metastatic tumors (ME-180/omentum, HT-3/lymph node, MS751/lymph node and CaSki/small intestine). Figure 1A shows that levels of DSS1 mRNA were significantly upregulated in all of these cervical carcinoma cell lines, compared with levels for two human normal fibroblast lines (HS68 and HNF) and one human normal keratinocytes (HNK), ranging from 6.6-to 13.8-fold ( Figure 1A) . Similar results were obtained by IB, which disclosed 4.6-to 13.2-fold increased expression of the DSS1 protein in the tumor cell lines, as compared with the nonmalignant fibroblasts and normal keratinocytes ( Figure 1B) . We next examined the expression patterns of DSS1 protein in a cohort of specimens from patients with cervical cancer, which were collected as 26 sets of individually matched normal and tumor tissue pairs from patients having various stages and/or grades of cervical cancer. DSS1 protein levels were low or undetectable in cells of normal cervical tissue from each of the specimen pairs ( Figure 1C ). In contrast, DSS1 protein was highly expressed in >96% of the tumor tissues in these specimen pairs, and higher expression levels of DSS1 protein were readily observed when comparing cells of tumor tissue with cells of the adjacent normal cervix. DSS1 protein levels in the cells of tumor tissues ranged from 1.5-to 371-fold when compared with normal cells (Figure 1C and 1D) .
Localization of DSS1 protein in tissue arrays of invasive cervical carcinoma cells and cells from precursor lesions
To investigate the clinicopathological relevance of upregulated DSS1 protein expression and cervical cancer development in patients, we detected and scored DSS1 protein levels using IHC in 145 cervical specimens blotted in tissue array slides. These 145 tissue specimens contained tumors ranging from CIN2 (n = 50) and CIN3/CIS (n = 48), and more invasive cancers including SCCs (n = 23) and non-SCCs [AdCs (n = 18) and AdSCCs (n = 6)]. As noted in the IB results in Figure 1C , DSS1 protein expression was undetectable or low in normal cervical epithelial cells (Figure 2A ), but high in the proliferative regions of all histological types of human cervical cancer ( Figure 2B ). Of 50 cases of CIN2, DSS1 expression was 0 in 2, 1+ in 11, 2+ in 24 and 3+ in 13 cases; and of 48 cases of CIN3/CIS, DSS1 expression was 0 in 4, 1+ in 9, 2+ in 18 and 3+ in 17 cases ( Figure 2C) . Notably, 73-74% of the tumor sections showing DSS1 staining scored >2+ were from tumors staged at CIN2 (37/50) or CIN3/CIS (35/48) and SCCs (17/23) ( Figure 2C and Supplementary Table 1, available at Carcinogenesis Online, respectively). However, 58% (14/24) of the tumor sections showing DSS1 staining scored >2+ were from non-SCCs including AdCs (9/18) and AdSCCs (5/6) (Supplementary Table 1 , available at Carcinogenesis Online). We also found that the ratios of strong DSS1 staining with score 3+ were significantly elevated in SCCs (57%) compared with CIN2 (26%) and CIN3 (35%) or normal cervical tissue (0%) ( Figure 2C ). When the data for DSS1 expression and clinicopathological factors were analyzed, there was a significant correlation between DSS1 expression by the tumor cells (with score 3+) and lymphovascular space involvement (LVSI) (P = 0.005) or tumor squamous cell histology (P = 0.031), respectively (Table 1) . However, multivariate logistic regression analysis identified that the only independent risk factor associated with strong DSS1 expression was LVSI (odds ratio, 4.583; 95% confidence interval, 1.127-18.636; P = 0.033) ( Table 1) . No significant correlation was detected for DSS1 expression and tumor grade, tumor size, cervical depth invasion or nodal metastasis (Table 1) . In most cases, DSS1 staining was most intense in the cytoplasm, although in some cases a prominent nuclear or cytoplasmic/nuclear staining of the protein was detected ( Figure 2B ).
Knockdown of endogenous DSS1 inhibits cellular proliferation and reverses neoplastic transformation
Our findings that DSS1 expression is elevated in cervical tumors suggest that DSS1 plays a pivotal role during the development of human cervical cancer. Therefore, we sought to determine whether the absence of functional DSS1 affects either cellular proliferation or focus-forming activity of cervical epithelial cells in culture, which has long been known to be necessary for cell transformation and clonal expansion of tumor cells (28) . As shown in Figure 3A (left), three independent stable clones of HeLa cells (HeLa/shDSS1-C2, -C3 and -C15) were generated which had endogenous DSS1 that was depleted 80-90% when compared with three independent negative control stable HeLa clones (HeLa/Hygro-C4, -C5 and -C20). All three HeLa/shDSS1 stable clones had a decreased cellular proliferation rate by 50-80% when compared with HeLa/Hygro stable clones in which DSS1 was unaltered ( Figure 3B ; left top). In addition, the HeLa/shDSS1 stable clones exhibited a reduced colony-forming activity by 75% in monolayer cell cultures when compared with HeLa/Hygro cells (Figure 3C and 3D ; left). Stable depletion of DSS1 also reduced the ability of transformed cells to proliferate in soft agar assays when comparing HeLa/shDSS1 cells with HeLa/Hygro cell clones (Figure 3E and 3F; left) . Notably, however, DSS1 knockdown did not affect proliferation, focus-formation and soft agar clonogenicity by C-33A and HT-3 cells, neither of which is infected by HPV (both are p53 mutated; Figure 3A-F; right) .
Knockdown of endogenous DSS1 causes cell death through p53-dependent pathway
HeLa/shDSS1 cell clones were also compared with negative control HeLa/Hygro cell clones for traits of cellular apoptosis. Figure 4A and 4B shows that cell detachment, cell shrinkage, membrane blebbing, cell pyknosis and margination of nuclear chromatin were readily detectable in HeLa/shDSS1 cells (e.g. C2, C3 and C15), whose DSS1 was knocked down, whereas no such effect was observed in the HeLa/ Hygro stable clones whose DSS1 levels were unaltered (e.g. C20). In The independent pGeneClip/NC1-and shDSS1-transduced stable clones were examined by IB using DSS1-specific antibody (1 µg/ml). Actin was used as an internal loading control. (B) HeLa, but not C-33A or HT-3, DSS1-knockdown stable clones lose growth advantage in monolayer cultures. Growth curves were generated for cells stably expressing NC1 (HeLa/Hygro-C4, -C5 and -C20; C-33A/Hygro-C1; or HT-3/Hygro-C1) or shDSS1 (HeLa/shDSS1-C2, -C3 and -C15; C-33A/shDSS1-C1; or HT-3/shDSS1-C2). Cells were plated at 1 × 10 4 /well onto 6-well plates and grown in MEM (HeLa and C-33A) or RPMI-1640 (HT-3) with 10% FBS in the presence of 400 µg/ml Hygromycin B. The medium was changed every 2-3 days and the cell numbers were counted in triplicate for the following 12 days. Data represent the mean ± SEM of three independent experiments. *HeLa/Hygro-C5 cell proliferation is significantly higher than that of HeLa/shDSS1-C15 cells (P < 0.01). **HeLa/Hygro-C5 is significantly greater than HeLa/shDSS1-C15 (P < 0.001). (C) and (D) × 10 2 )] were seeded and selected in 400 µg/ml Hygromycin B for 2-3 weeks. Foci were stained with 1% rhodamine B for 1 h at room temperature. The numbers of foci were counted in triplicate. Data represent the mean ± SEM of three independent experiments. *HeLa/Hygro-C4 is significantly greater than HeLa/shDSS1-C2 (P < 0.005).
† HeLa/Hygro-C20 is significantly greater than HeLa/shDSS1-C15 (P < 0.005). (E) and (F) Anchorage independence assay in soft agar. DSS1-knockdown and DSS1-intact cells at a cell density of 1 × 10 4 were layered in soft agar in the presence of Hygromycin B (400 µg/ml) to maintain selection. Colonies with >8 cells were counted, photographed and indicated by solid arrows. Data represent the mean ± SEM of three independent experiments. Micrographs, ×10 for low and ×40 for high magnification. Scale bar: 100 µm. *HeLa/Hygro-C4 is significantly greater than HeLa/shDSS1-C2 (P < 0.005).
† HeLa/Hygro-C20 is significantly greater than HeLa/shDSS1-C15 (P < 0.0006).
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addition, DNA fragmentation, with multiple internucleosomal fragments of 180 bp, were clearly observed in DNA from HeLa/shDSS1 stable clones (C2 and C15) when compared with HeLa/Hygro stable clones, C4 and C20, which did not display the pattern of DNA laddering ( Figure 4C ; left panel). Again, the C-33A/shDSS1-C1 or HT-3/shDSS1-C2 cells showed no change in cell morphology under DSS1 knockdown conditions (data not shown) and DNA fragmentation did not occur in the DSS1-knockdown C-33A/shDSS1-C1 or HT-3/shDSS1-C2 cells ( Figure 4C ; middle and right panels). Taken together, these data indicate that depletion of endogenous DSS1 expression in p53-intact, HPV-transformed cervical epithelial cancer cells causes cell death through apoptosis, whereas cervical carcinoma cells not infected with HPV (with p53 mutations) show no such effects.We have shown previously that the DSS1 protein physically interacts with the RPN3/S3 proteasomal subunit, which in turn increases the degradation of ubiquitinated p53, thereby preventing apoptosis of abnormal cells via the p53 pathway (25) . To determine whether knockdown of DSS1 in immortalized cervical carcinoma cells might cause apoptosis of these cells via p53, we first compared p53 protein levels and apoptotic markers in HeLa/shDSS1 stable clones (C2 and C15) and HeLa/Hygro stable clones (C4 and C20). In addition, we examined whether DSS1 knockdown affects p53 or apoptosis in human cervical carcinoma cell lines whose p53 gene is mutated: C-33A (p53 mutR273C ) and HT-3 (p53 mutG245V
). As shown in Figure 4D , HeLa/shDSS1 stable clones, C2 and C15, had significantly elevated levels of p53 and the p53 downstream responsive gene product p21 WAF1/CIP1 when compared with HeLa/Hygro stable clones, C4 and C20. In contrast, levels of p53 in the C-33A and HT-3 cells were unchanged upon DSS1 knockdown ( Figure 4D ). In addition, cleavage fragments of apoptosis-associated targets, including CPP32/caspase-3, PARP and DNA-PKcs, were detected in the HeLa/shDSS1 stable clones (C2 and C15), but not in the HeLa/ Hygro stable clones (C4 and C20), nor were the cleavage fragments detected in C-33A/shDSS1-C1 cells, or HT-3/shDSS1-C2 cells with depleted DSS1 (Figure 4D ). To further confirm that p53 is really the inducer of apoptosis, p53 expression was knocked down using a specific siRNA in a background of downregulated DSS1 stable clones, including HeLa/shDSS1-C2 and -C15. As compared with the NC1-knockdown control clones, DNA laddering patterns did not appear in DNA preparations from p53-knockdown HeLa/shDSS1-C2 and Characteristics of apoptosis like cell shrinkage and membrane blebbing, indicated by solid arrows, were conspicuous as seen under light microscopy in HeLa/shDSS1-C2, -C3 and -C15 cells, whereas no such effects were observed in HeLa/Hygro-C20 control cells. Micrographs, ×10 for low and ×20 and ×40 for high magnification. Scale bar: 100 µm. (C) DNA laddering patterns for DSS1-knockdown versus DSS1-intact cells. DNA fragmentation patterns were clearly observed in DNA preparations from the HeLa DSS1-knockdown clones (HeLa/shDSS1-C2 and -C15), but was not observed in the control clones from HeLa (HeLa/Hygro-C4 and -C20), C-33A (C-33A/Hygro-C1) and HT-3 (HT-3/Hygro-C1), or in the DSS1-knockdown C-33A/shDSS1-C1 and HT-3/ shDSS1-C2 cells. (D) Immunoblots of lysates (20 µg) were prepared from DSS1-knockdown clones HeLa/shDSS1-C2 and -C15, DSS1-intact HeLa/Hygro-C4 and -C20 and p53-mutant, DSS1-knockdown C-33A/shDSS1-C1 and HT-3/shDSS1-C2 cells. The blots were incubated with antibodies against DSS1 (1 µg/ ml), p53 (1:1000), p21 WAF1/CIP1 (1:1000), CPP32/caspase-3 (1:1000), PARP (1:1000), DNA-PKcs (1:1000) and actin (1:2000) (serves as a loading control). (E) Knockdown of p53 in stable clones with a background of downregulated DSS1 rescues cells from death by apoptosis. RNAi transfections were carried out using 100 nM silencer® select validated negative control 1 (NC1) and human p53-specific siRNAs (Ambion; #4390824) (sense: GUAAUCUACUGGGACGGAAtt; antisense: UUCCGUCCCAGUAGAUUACca) in DSS1-knockdown cells, HeLa/shDSS1-C2 and -C15. In brief, cells (2 × 10 6 ) were electroporated by using program I-013 of the Nucleofector Device (Amaxa). Cells were then cultured and harvested for protein preparation at 48 h after electroporation. The protein levels knocked down by siRNAs were examined by using IB with a specific anti-p53 antibody as indicated. DNA laddering patterns were clearly reduced in DNA preparations from p53-knockdown HeLa/shDSS1-C2 and -C15 stable clones.
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-C15 stable clones ( Figure 4E ). Thus, knocking down 80% of p53 expression in protein level can rescue DSS1-knockdown cells (HeLa/ shDSS1-C2 and -C15) from death by apoptosis. Taken together, these data suggest that sustained DSS1 expression suppresses p53 expression and p53-dependent apoptosis in cervical squamous epithelial cells, and that removal of functional DSS1 can reverse the apoptotic defect in cells with wild-type p53 but not mutant p53.
The effects of DSS1 overexpression and knockdown on cisplatin cytotoxicity
To investigate the possible involvement of DSS1 overexpression in the resistance of human cervical epithelial cancer cells to cisplatin, HeLa cell clones, stably expressing HTBH or DSS1-HTBH, were treated with cisplatin at concentrations ranging from 6.25 to 50 µM for 48 h followed by a CellTiter 96® AQ ueous One Solution Cell Proliferation (MTS) assay. As shown in Figure 5A , the protein expression was detected by IB using streptavidin-HRP at a physiological level in HeLa/HTBH (C2 and C16) and HeLa/DSS1-HTBH (C9 and C22) stable clones. In addition, overexpression of DSS1 led to a significant increase in cell viability after treatment with 12.5 µM cisplatin in stable clone HeLa/DSS1-HTBH-C9 compared with the HeLa/HTBH-C2 control cells (*P < 0.001) ( Figure 5B) . Interestingly, the cisplatin IC 50 was significantly higher in HeLa/DSS1-HTBH (C9 and C22) versus HeLa/HTBH (C2 and C16) control cells ( Figure 5B ). Our results suggest that ectopically enforced constitutive expression of DSS1 can enhance the chemoresistance of human cervical cancer cells to cisplatin. On the contrary, to determine whether downregulation of DSS1 expression can sensitize human cervical cancer cells to cisplatin and cause cell death. To address this, DSS1-knockdown (HeLa/shDSS1-C2 and -C15) and DSS1-intact (HeLa/Hygro-C4 and -C20) cells were treated with various concentrations of cisplatin for 48 h, followed by incubation with MTS reagents for 4 h. Cell viability was significantly inhibited after treatment with cisplatin at 12.5 (*P < 0.005) and 25 µM (**P < 0.005) in HeLa/shDSS1-C2 and -C15 cells, as compared with HeLa/Hygro-C4 and -C20 control cells ( Figure 5C ).
Discussion
The goal of this study was to better understand the role of DSS1 in the molecular pathogenesis of human cervical cancer by using welldefined clinical specimens and in vitro cell culture model systems. Here, we have demonstrated five principal findings: (i) DSS1 mRNA and/or protein are overexpressed in human cervical carcinoma cell lines and in tumors from patients with high grades and/or stages of cervical cancer ( Figure 1) ; (ii) in cervical tissue, DSS1 protein is specifically expressed and localized in the highly proliferative squamous or glandular regions, and is elevated early during high-grade squamous intraepithelial lesions (HSIL) ( Figure 2) ; (iii) knockdown of endogenous DSS1 inhibits proliferation, reduces focus-forming activity and prevents the proliferation of cancerous cervical epithelial cells in soft agar ( Figure 3) ; (iv) functional knockdown of DSS1 results in apoptosis mediated through a functional p53-dependent signaling pathway ( Figure 4) ; and (v) silencing of DSS1 confers sensitivity to the DNAdamaging agent cisplatin in human cervical cancer cells ( Figure 5 ). We conclude that DSS1 protein is a novel biomarker for early detection, diagnosis and treatment of human cervical carcinomas.
A previous study from our laboratory showed that constitutive expression of DSS1 in JB6 Cl 41-5a preneoplastic epidermal cells was positively correlated with increased cell growth rate, elevated focusforming ability and enhanced cellular transformation, suggesting that DSS1 has oncogenic properties in early skin carcinogenesis (22) . DSS1 mRNA was highly expressed and localized to the rapidly proliferative squamous regions of TPA-induced papillomas and malignancies, with some expression in the adjacent epidermis and hair follicles (22) . DSS1 protein was also markedly increased in TPA-induced skin hyperplasia, papillomas and malignant tumors in mice (22) , and was also significantly upregulated in UV-induced SCCs (32) . In agreement with these previous results, we have shown here that DSS1 is highly expressed in metaplastic squamous or glandular tissues, and that it is elevated even more in HSIL, including CIN2 and CIN3/CIS ( Figure 2B and 2C). These data suggest to us that upregulation of DSS1 protein is a critical event during the progression of precancerous lesions into more invasive cervical carcinomas. It will be interesting to determine whether DSS1 upregulation is a universal event for epithelial cell carcinogenesis or whether it is limited to specific epithelial cell types.
Notably, cervical cancer patients with LVSI had tumors whose cells exhibited a significant increase in DSS1 protein expression levels (strong staining with score of 3+) when compared with tumors from patients without LVSI (Table 1 and Supplementary Table 1, available at Carcinogenesis Online). Several studies have recently identified LVSI as an independent surgical-pathological predictor of recurrence, exclusively for bulky stage IB cervical cancer, and LVSI is used as a significant prognostic factor for shortened disease-free survival, despite an early stage cervical cancer diagnosis (33, 34) . Although LVSI as an independent risk factor is controversial, it has been shown to be one of the independent predicting factors for pelvic node metastases in numerous peer-reviewed studies (35, 36) . This nodal status is considered to be the major prognostic factor affecting survival among women with early stage cervical cancer (37, 38) . Currently, LVSI is one of three intermediate-risk factors predictive of early invasive cervical carcinoma after radical surgery, and all three may be useful in decision making for the use of post-operative adjuvant radiation therapy. Our results strongly suggest that upregulation of DSS1 protein expression is potentially positively correlated with the risk of tumor recurrence and negatively associated with disease-free survival in early stage cervical cancer patients with no apparent lymph node metastasis. Therefore, it will be important to assess clinical relevance of DSS1 expression for the cases of advanced-stage cervical cancer with concurrent cisplatin-based chemoradiation, which is a standard therapy at present, to determine whether tumors whose cells have strong DSS1 expression (3+), either in the cytoplasm and/or nucleus, predict tumor recurrence and a shorter survival time.
Cervical cancer patients are almost always infected by high-risk types of HPV such as 16, 18, 31, 33 and 45 (27) . However, only 10% of HPV-infected patients will develop a series of precancerous lesions, including LSIL and HSIL, and only about 0.8% of cases will progress to the more invasive cervical cancers like SCCs and AdCs (1, 4) . In a mouse model for cervical cancer, where the HPV16 oncogenes, E6 and E7, have been transduced into the normal cervix, tumor promoters like TPA or mutagens such as N-methyl-N′-nitro-N-nitrosoguanidine promote tumor development in a dose-dependent fashion (39) . This work indicates that HPV acts as an initiator to induce intraepithelial dysplasic changes, although oncoprotein expression in infected cells is not sufficient to trigger tumor formation. Thus, a cofactor is required to promote cervical neoplastic progression. Here, we have provided data that support our central hypothesis that DSS1 plays a pivotal role in the molecular pathogenesis of human cervical cancer. It follows that agents or events that elevate levels of DSS1 may provide the second event, or cofactor, necessary for full transformation of oncogenic HPV-infected cervical cells. Although we did not detect the expression level of DSS1 protein in patient 17, it could be due to association of any other pathways like PIK3CA, which is frequently involved in cellular proliferation (immortality) and neoplastic (malignant) transformation during the development of cervical cancer (9) .
Previous studies have shown that treatment of human cervical carcinoma cells with the proteasome inhibitor, bortezomib, restores normal expression levels and functions of p53, which in turn triggers the death of the treated cells through the CPP32/caspase-3-dependent apoptotic pathway (40) . It is interesting in this regard that HPVpositive cervical cancer cells are more sensitive to bortezomib or to another proteasome inhibitor, MG-132, than are HPV-negative cervical cancer cells or primary human keratinocytes (40, 41) . Additionally, downregulation of HPV16 or HPV18 E6/E7 by specific E6 siRNA also leads to growth inhibition of HPV16 or HPV18-positive cervical cancer cells, and eventually causes cell death via CPP32/caspase-3-mediated p53-dependent apoptosis (42, 43) . More recent work has shown that targeting E6 or XIAP in combination with cisplatin can efficiently potentiate rhTRAIL-induced CPP32/caspase-8/-3-mediated apoptosis in HPV-positive cervical cancer cells (44) . In this study, we have shown that DSS1 expression is upregulated in cervical tumors, and that enforced downregulation of DSS1 in tumor cells makes them susceptible to apoptosis in a p53-dependent manner, suggesting that the proteasome, HPV oncoproteins and DSS1 function in a linear pathway to disturb regulatory mechanisms that govern cervical epithelial cell proliferation and apoptosis. It will be important now to determine how oncogenic HPV infection affects DSS1 expression immediately after infection, because a cause and effect relationship has not yet been established.
In summary, this research is innovative in identifying the DSS1 protein as a novel potential biomarker for early detection, diagnosis and treatment of human cervical cancer. First, we have demonstrated that DSS1 is specifically expressed and localized in the highly proliferative regions of the human cervical carcinoma. Secondly, tumors from patients with higher grades and/or stages of cervical cancer contain cells with significantly higher levels of DSS1 expression, compared with cells from tumor-adjacent normal cervical tissue. Thirdly, we have more fully elucidated the mechanisms by which knockdown of DSS1 expression causes cell death and reverses neoplastic transformation of cervical cancer cells in vitro. Lastly, our results point to a novel therapeutic strategy that may reverse tumor cell drug resistance (e.g. cisplatin) through inactivation of DSS1 expression in the cells.
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